TSHA

3.7201.33%
SP

Sean P. Nolan

CEO & Chairman

Mr. Sean P. Nolan serves as an Independent Director of Ventas, Inc. since July 26, 2019. He is Chairman of Encoded Therapeutics, Inc. from 2018. He is Executive Chairman of the Board of Istari Oncology, Inc. He is Independent Chairman of the Board of Affinia Therapeutics, Inc. from December 2019. He is CEO & Chairman of Taysha Gene Therapies, Inc. from December 2022. He was Independent Chairman of the Board of Taysha Gene Therapies, Inc. from March 2020 to December 2022. He is Executive Chairman of Jaguar Gene Therapy, LLC. He was Chief Business Officer and Executive Vice President of InterMune, Inc. He joined InterMune, Inc. in February 2013. He was President & CEO of Novartis Gene Therapies, Inc. from May 15, 2018. He was CEO, President & Director of Novartis Gene Therapies, Inc. from June 2015 to May 15, 2018. He joined the Novartis Gene Therapies, Inc. on June 18, 2015. He was Independent Director of Neoleukin Therapeutics, Inc. from February 16, 2015, to June 01, 2020. He was employed at Neoleukin Therapeutics, Inc. from February 16, 2015, to June 01, 2020. He was Chief Commercial Officer and Vice President of Reata Pharmaceuticals, Inc. He joined Reata Pharmaceuticals, Inc. on October 14, 2011. He was Chief Executive Officer of Lundbeck Inc. He joined Lundbeck Inc. in December 2009. He was Independent Director of Social Capital Suvretta Holdings Corp. II from September 24, 2021, to July 31, 2023. He was employed at Social Capital Suvretta Holdings Corp. II until July 31, 2023. He has B.S. in Biology from John Carroll University.

Positions